... Administrationapproval of sorafenib and sunitinib, which target vascularendothelial growth factor receptor, platelet-derivedgrowth factor receptor, FLT-3, and c-Kit, marks the use of a new generation of multitarget ... 1State Key Laboratory of Oncology in South China and the Department of Experimental Research, Sun Yat-sen University Cancer Center, Guangzhou, PR China and 2Ascenta Therapeutics Incorporation, ... theefficacy and tolerability of these targeted agents hasshown that most tumors depend on more than one sign-aling pathway for their growth and survival. Therefore,investigators pursue different strategies...